Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts

Archive ouverte

Dieden, Anna | Girerd, Nicolas | Ottosson, Filip | Molvin, John | Pareek, Manan | Melander, Olle | Bachus, Erasmus | Råstam, Lennart | Lindblad, Ulf | Daka, Bledar | Leósdóttir, Margrét | Nilsson, Peter, M | Olsen, Michael, H | Clark, Andrew, L | Cleland, John G.F. | Delles, Christian | González, Arantxa | Lamiral, Zohra | Duarte, Kevin | Rossignol, Patrick | Zannad, Faiez | Gudmundsson, Petri | Jujić, Amra | Magnusson, Martin

Edité par CCSD ; European Society of Cardiology (Wiley) -

International audience. ABSTRACT Aims Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population‐based cohorts. Methods and results A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.4%) and, over a median follow‐up of 13 (11–14) years, 130 developed HF (7.7%). Findings were confirmed in the STANISLAS ( n > 1500, 238 participants with LVH, 76 with DD) and HOMAGE case‐control (562 cases of incident HF, 871 controls) cohorts. In multivariable logistic or Cox regression analyses adjusted for age, sex and cardiovascular risk factors, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) was associated with LVH, DD and incident HF in all cohorts: MPP (LVH odds ratio [OR] [95% confidence interval] 1.48 [1.28–1.71]; DD OR 1.71 [1.53–1.92]; HF HR 1.98 [1.66–2.36]); STANISLAS (LVH OR 1.20 [1.02–1.41]; DD OR 1.46 [1.12–1.90]); HOMAGE (HF HR 1.85 [1.62–2.12]). Galectin‐4, growth differentiation factor 15 and suppression of tumorigenicity‐2 were associated with incident HF in MPP and HOMAGE. A pathway enrichment analysis suggested that inflammation and viral infection were related to incident HF. Conclusion In conclusion, our study reinforces the role of NT‐proBNP as a key biomarker for asymptomatic cardiac dysfunction and incident HF, consistent with its established use in clinical practice. This underscores the value of NT‐proBNP for identifying patients at high risk for HF, and provides insights into pathways leading to HF and potential therapeutic targets.

Suggestions

Du même auteur

Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals

Archive ouverte | Kobayashi, Masatake | CCSD

International audience. Objectives: This study sought to identify homogenous echocardiographic phenotypes in community-based cohorts and assess their association with outcomes.Background: Asymptomatic cardiac dysfun...

Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort

Archive ouverte | Kobayashi, Masatake | CCSD

International audience. Aims High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characterist...

Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial

Archive ouverte | Monzo, Luca | CCSD

International audience. Background Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure and function, thereby increasing the risk of heart failure (HF). We aimed to ide...

Chargement des enrichissements...